Introduction
============

Renal cell carcinoma (RCC) accounts for more than 2% of neoplasias in humans worldwide [@B1]. In European Union the mean incidence is 16.8 per 100,000 person-years [@B2]. It is more often diagnosed in men than in women (M/F: 2/1). Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, which accounts for 60-65% of all renal cancers.

Currently, methods such as imaging techniques and biopsy are used to detect ccRCC [@B3]. Nevertheless, the most utilized imaging techniques indicate the size of tumors but not the morphology. On the other hand, the percutaneous renal tumour biopsy is the gold standard for diagnosis, especially for radiologically indeterminate renal masses, but it is invasive and not suitable for all patients. Therefore, new reliable and non-invasive biomarkers for ccRCC detection are required.

Urinary sample can be a non-invasive approach for discovering diagnostic biomarkers. Whole urine or urinary sediments were analyzed in several studies [@B4]-[@B6]. Recent findings have shown that a heterogeneous population of nanosized structures (i.e. microvesicles, apoptotic vesicles and exosomes) called extracellular vesicles (EVs), surrounded by a membrane composed of a phospholipid bilayer, is a component of urine, like other biofluids. They contain a wide variety of proteins and RNAs (mRNAs, miRNAs and non-coding RNAs) that represent the tissue of origin. The RNA encapsulated in EVs is termed exosomal shuttle RNA (esRNA). It can be transferred to recipient cells and can modulate their transcriptome.

Abundance of esRNA is poor in urinary EVs; therefore, the isolation and downstream RNA analysis are challenging [@B7]. A few studies have used microarrays [@B8] or real time quantitative PCR assays [@B9] to examine esRNA. Recently, the comparison of the protein profile of urinary EVs derived from RCC patients has been carried out by Raimondo et al. [@B10]. This study has shown a specific protein profile.

In this study, we have performed the transcriptome analysis of esRNA obtained from urinary EVs of ccRCC patients. The esRNA content was significantly different in ccRCC patients compared to healthy subjects (HS) and patients with other types of RCC. We identified three EV transcripts involved in the tumor biology that may be considered a potential diagnostic three-gene signature for ccRCC.

Materials and Methods
=====================

Patients
--------

Approval was obtained from the local ethics committee and written informed consent was obtained from all patients.

Midstream samples of the second morning urine samples were obtained from 33 untreated patients with ccRCC, before and after partial or radical nephrectomy. Urine samples were obtained during the first post-operative clinic. In this study we considered only adult patients who underwent nephrectomy with the following criteria: solid renal mass ranging from 1.5 to 7 cm; pathologically confirmed diagnosis of ccRCC with low-Fuhrman-grade (I or II); absence of distant metastasis; no treatment before nephrectomy. We collected and processed also urine samples from 22 HS as controls and from 13 patients with non-clear cell RCC (non-ccRCC) before nephrectomy in the same way as the ccRCC patients. They included 7 papillary RCC and 6 chromophobe RCC of similar age and sex. Table [1](#T1){ref-type="table"} shows the demographic and clinical characteristics of 33 patients with ccRCC, the tumor size, grade, as well as a composite of 22 HS and 13 non-ccRCC.

EVs and esRNA isolation
-----------------------

Briefly, 50 ml of urine was initially centrifuged at 300xg for 10 min to pellet whole cell contaminants. The supernatant was carefully removed and centrifuged at 17,000xg for 20 min to pull down cell fragments and apoptotic cells. The supernatant was then removed and filtered through a 0.8 mm filter to separate residual debris from the EV containing supernatant. Finally, the filtrate underwent ultracentrifugation at 118,000xg for 70 min, the supernatant was removed and the EV pellet washed in PBS. Total RNA, including small RNA (\<200 nt), was isolated using the miRCURY RNA isolation kit (Exiqon, Vedbaek, Denmark) following the manufacturer\'s instructions. Then, an aliquot was run on a RNA Pico 6000 chip (Agilent Tech, Santa Clara, CA, USA) using an Agilent Bioanalyzer 2100 instrument (Agilent Tech) to assess quantity and integrity.

Microarray Screening
--------------------

The Whole-Genome cDNA mediated annealing, selection, extension, and ligation (DASL) HT assay (Illumina, San Diego, CA, USA) was used to amplify the RNA for gene expression profiling. Briefly, 50 ng of each sample was reverse transcribed to cDNA and annealed to the DASL assay probe groups, which consisted of 29,285 oligonucleotides. Biotin-labeled cRNA was hybridized to Illumina HumanHT-12 v4 BeadChip microarrays and scanned. Array results were analyzed using GeneSpring GX 11.0 (Agilent Tech) to identify genes that had statistically significantly changed expression between groups. We checked and excluded the batch error by principal component analysis (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). Identification of genes differentially expressed between esRNAs from ccRCC patients and HS was carried out with FDR method of Benjamini-Hochberg and gene probe sets were filtered on the basis of the false discovery rate, FDR, (adjusted-P value with multiple testing on 1000 permutations) and fold-change. Fold change filter was set to 2-fold in each comparison. Only genes that were significantly (adjusted-P value \<0.05 and fold-change \>2) modulated were considered for further analysis.

To assess biological relationships among differently regulated genes, we used the Ingenuity Pathway Analysis software (IPA) (Ingenuity Systems, Redwood City, CA, USA; <http://www.ingenuity.com>). IPA generates networks based on the connectivity of the genes and computes a score for each network according to the fit of the set of supplied focus genes. These scores indicate the likelihood of focus genes to belong to a network versus those obtained by chance. Fischer\'s exact test with FDR option was used to calculate the significance of the canonical pathway. The computational analysis of the scientific literature was performed using the PubGene tool in Coremine Medical (<http://www.coremine.com/medical>) [@B11].

The Illumina microarray data are MIAME compliant and the raw data have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE72922.

Validation by qRT-PCR
---------------------

Quantitative real-time PCR (qRT-PCR) was used to validate the differential expression of selected genes. Reverse transcription and cDNA amplification were performed using the Complete Whole Transcriptome Amplification Kit (Sigma-Aldrich, Saint Louis, MO, USA) according to the manufacturer\'s instructions. qRT-PCR was performed using Sso Advanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) on a final volume of 20 μl using a StepOne Plus thermocycler (Applied Biosystems, Foster City, CA, USA). The primers used for the qRT-PCR analysis of GSTA1, CEBPA, PCBD1, PDCD6IP, GAPDH were purchased from QuantiTect Primer Assays (Qiagen, Hilden, Germany); the product numbers of the used primers were QT01671530, QT00203357, QT00001841, QT00067942, and QT00079247, respectively. The commercially primers were designed and optimized for qRT-PCR assay using SYBR green detection. Each assay was done in triplicate and the mean threshold cycle (Ct) was calculated. We calculated the 2^-ΔCT^ of expression profiles normalized to the expression of the control gene GAPDH.

Statistical analysis
--------------------

For qRT-PCR data, statistical analysis was carried out by using a two-tailed t-test. A P-value\<0.05 was considered as significant.

Results
=======

Isolation and transcriptome analysis of esRNA
---------------------------------------------

We isolated esRNA from the urine samples of 22 HS, 33 untreated patients with ccRCC and 13 untreated patients with non-ccRCC of similar age and sex. For transcriptome profiling, we extracted total RNA from purified EVs. The extracted nucleic acid material was assessed for size distribution and quality using the Agilent Bioanalyzer (Figure [1](#F1){ref-type="fig"}), which demonstrated two high rRNA peaks (18S and 28S) that were enriched in short RNA such as mRNA and miRNA. Figure [1](#F1){ref-type="fig"} shows the small RNA peak between 25 and 200 nucleotides, and enough ribosomal RNA with a profile similar to that observed by Miranda et al. [@B12]. To confirm the identity of the source of the RNA preparations, the mRNA of the EV biomarker PDCD6IP (also known as ALIX) was used for the qRT-PCR and demonstrated to be present \[not shown\].

Transcriptome profiles of urinary EVs from 12 patients with ccRCC and 11 HS belonging to the training group were generated using the Illumina HumanHT-12 v4 BeadChip oligonucleotide arrays interrogating \>29,000 genes. In the esRNA we detected a mean of 2213 genes.

Microarray analysis revealed the differential expression of 70 genes that were significantly modulated in the ccRCC compared to the HS with a fold change of 1.5 and a false discovery rate \<0.05 (Figure [2](#F2){ref-type="fig"}A and Supplementary Table [1](#SM1){ref-type="supplementary-material"}). The principal component analysis (PCA) showed that these genes could clearly distinguish the ccRCC patients from the healthy cohort (Figure [2](#F2){ref-type="fig"}B) only starting from genes differentially modulated, excluding that the separation could be ascribed to a batch effect (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

We performed the pathway analysis on the modulated genes and we found several biological pathways that were significantly modulated in ccRCC patients compared to HS. In particular, among the most significant networks we found "developmental disorder", "cancer", "cell cycle" and "cell death and survival" (Figure [3](#F3){ref-type="fig"} and Supplementary Table [2](#SM1){ref-type="supplementary-material"}).

Moreover, we performed a computational analysis of the scientific literature to evidence modulated genes directly or indirectly involved in the biological processes of RCC. We found that, on the basis of the literature, 24 of 70 modulated genes were involved in biological processes activated in RCC (Figure [4](#F4){ref-type="fig"}). Some of these were involved also in the evidenced pathways of "cell death and survival", "cancer" and "developmental disorder", as *GSTA1*, *CEBPA* and *PCBD1*, respectively.

Gene signature validation
-------------------------

In order to validate our findings obtained with microarray analyses, we performed qRT-PCR analysis of the three genes in the urinary esRNA from an independent cohort of 33 RCC patients, of whom 20 with ccRCC and 13 with non-ccRCC.

The qRT-PCR findings were broadly consistent with our microarray data (Figure [5](#F5){ref-type="fig"}). We observed that *GSTA1* esRNA expression was significantly decreased in ccRCC patients compared to the group of HS. This alteration trend in gene expression was also observed for the transcription *CEBPA* gene, a general inhibitor of cell proliferation and a tumor suppressor. Also *PCBD1*, which codes for a coactivator of HNF1A-dependent transcription, had a low gene expression in patients affected by ccRCC compared to HS.

Next, we interrogated this three-gene signature in a cohort of patients with non-ccRCC, consisting of papillary and chromophobe cell type (Figure [5](#F5){ref-type="fig"}). Interestingly, non-ccRCC patients had significantly higher *GSTA1*, *CEBPA* and *PCBD1* esRNA transcript levels, indicating that our gene signature is tumor histotype specific. In particular, in chromophobe RCC patients the esRNA levels of *GSTA1* and *PCBD1* were similar to that of HS, whereas the *CEBPA* levels were very higher compared to both HS and ccRCC patients. In papillary RCC patients, the *PCBD1* levels were similar to that of HS, whereas the amount of *GSTA1* and *CEBPA* transcripts was higher compared to both HS and ccRCC patients.

Then, we compared esRNA levels of *GSTA*, *CEBPA* and *PCBD1* before and after nephrectomy. After tumour removal esRNA levels of these three genes significantly increased compared to that of pre-surgery values and HS (Figure [6](#F6){ref-type="fig"}).

These results suggest that the *GSTA1*, *CEBPA* and *PCBD1* esRNA signature may be considered a potential diagnostic pattern for ccRCC.

Discussions
===========

EV secretion appears to be a common feature of neoplasia. Consistently, they increase in blood and urine. Cancer-derived EVs reflect the original cancer cells and esRNA extracted from them contains a snap of the cancer transcriptome [@B13].

They have been widely studied in the last few years and seem to have several functions such as intercellular communication, expressing signaling pathway activation through growth factor/receptor transfer, induction of angiogenesis and immune regulation [@B14]-[@B21]. esRNA is protected from urinary ribonuclease degradation by packaging in EVs [@B22].

To validate the concept of urinary EVs as potential source of new cancer biomarkers for ccRCC, we carried out a study to compare gene expression for the identification of esRNA as tools useful for the ccRCC diagnosis. Our initial bioanalyzer data showed that isolated esRNA had a fragment length ranging between the small (\<200 nt) and the large (\>200 nt) RNA fractions. Since we isolated a low amount of esRNA, we used a pre-amplification step for the qRT-PCR validation.

Analysis of urinary EV transcripts revealed *GSTA1* decreased in ccRCC when compared to HS. Interestingly, the function of GST-α is to protect cell by catalyzing the detoxification of xenobiotics and carcinogens. In renal tissue three cytosolic isoenzymatic GSTs have been identified, which are mentioned as α, μ, and π. The location of these isoenzymes is different along the nephron. GST-α is expressed principally in the convoluted proximal tubule where ccRCC usually is supposed to origin [@B23]. Our data is in agreement with those of several authors who reported a decreased level of GST-α expression in tumor tissue of patients with RCC as determined by Northern or Western blotting [@B24]-[@B26] but these findings are in disagreement with the findings of other studies where glutathione S-transferase A was highly expressed in RCC tumor tissue by immunostaining and correlated with histology [@B27].

We also found a decreased *CEBPA* expression in ccRCC urinary EVs when compared to HS samples. C/EBPs comprise a family of transcription factors of which *CEBPA* plays an important role in normal tissue development and in the regulation of cell proliferation and cell differentiation [@B28]. Some experiments established that various molecular mechanisms control *CEBPA* expression or function in various types of cancers. Our findings are consistent with an early study of CEBPA in tumor tissue samples from RCC patients. Protein levels of tumor suppressor CEBPA have been reported to be downregulated in the pools of tumor tissues when compared to that of normal tissues [@B29].

Another interesting aspect of our study was the significant decrease of *PCBD1* in the ccRCC urinary EVs. The multifunctional protein PCBD1 is a cofactor for the HNF1 homeobox transcription factor that stabilizes HNF1α dimers and enhances its transcriptional activity. It can assemble a stable tetrameric PCBD1-HNF1α leaving unchanged DNA binding properties of HNF1α [@B30]. Our results are supported by an interestingly analysis of the RCC samples by western blotting that revealed considerably less levels of HNF1α compared to the control tissue [@B24].

Then, the expression of these three esRNAs was confirmed by qRT-PCR in the validation group.

We also found differences in the expression level of these three exosomal transcripts between the different histotypes of RCC, with highest expression in papillary and chromophobe RCC compared with ccRCC. This data is consistent with previous mRNA and cytogenetic data showing that different histotypes are not only different in their morphological appearance but also in their molecular characteristics [@B31].

Moreover, our qRT-PCR results revealed that at one month after tumor eradication the levels of *GSTA1*, *CEBPA* and *PCBD1* increased significantly, reaching the expression levels of HS.

Taken together these results support the definition of a specific histotype esRNA gene signature able to distinguish low-Fuhrman-grade ccRCC patients from HS and from non-ccRCC.
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![**Urinary EVs RNA integrity.**RNA isolated from urinary EVs was shown to be of high integrity with prominent 18S and 28S rRNA peaks when analyzed using the Agilent Bioanalyzer.](jcav07p1960g002){#F1}

![P**rincipal component analysis of the gene expression**. A) Volcano plot showing 70 genes that were significantly modulated in the ccRCC compared to the HS with a fold change of 1.5 and a false discovery rate \<0.05. B) Principal component analysis 3-D diagram showed different spatial distribution of the ccRCC (blue) and HS (red) populations. The two groups had significant differences in gene expression distribution and indicated two transcriptionally distant populations.](jcav07p1960g003){#F2}

![**Altered canonical pathways associated with ccRCC**. The canonical pathways are shown along the y-axis of the bar chart. The x-axis indicates the statistical significance. Interestingly, "developmental disorder", "cancer", "cell cycle" and "cell death and survival" were found the most significant identified canonical pathways in ccRCC.](jcav07p1960g004){#F3}

![**Computational analysis of the scientific literature**. Computational analysis of the scientific literature evidences 24 modulated genes that are involved in biological processes activated in RCC using the COREMINE online database/tool.](jcav07p1960g005){#F4}

![**Validation of *GSTA1*, *CEBPA*, *PCBD1* esRNA levels**. Levels of *GSTA1*, *CEBPA*, *PCBD1* were validated by qRT-PCR in an independent cohort of 20 ccRCC patients and 10 HS. Results showed a significant decrease in levels of *GSTA1*, *CEBPA* and *PCBD1* esRNA in ccRCC compared to both HS and chromophobe RCC (chRCC) and papillary RCC (pRCC). Samples have been standardized for GAPDH. Data represent the means ± s.d. Different asterisks (\*) indicate significant differences (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001).](jcav07p1960g006){#F5}

![**Increased level of *GSTA1, CEBPA*, and *PCBD1*esRNA after nephrectomy.***GSTA*, *CEBPA* and *PCBD1* esRNA levels significantly increased at 1 month after nephrectomy compared to their basal levels. Samples have been standardized for GAPDH. Data represent the means ± s.d. Different asterisks (\*) indicate significant differences (\*, P \< 0.05; \*\*, P \< 0.01).](jcav07p1960g007){#F6}

###### 

Demographic and clinical characteristics of patients with clear cell RCC (ccRCC), chromophobe RCC (chRCC), papillary RCC (pRCC) and healthy subjects (HS).
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